subretinal injection of rAAV.hPDE6A

Phase 2Gene therapy

subretinal injection of rAAV.hPDE6A is one of 17 small molecule programs targeting Retinitis Pigmentosa. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaActive, not recruiting

Retinitis PigmentosaPhase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Trexall

Plaquenil

Bendopa

MMerz North America, Inc.

Lodosyn

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Minocin

TTriax

Phase 3

2 8

Neoral

BS01

1 10

Human Retinal Progenitor Cells

JjCyte, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Active, not recruiting

Retinitis Pigmentosa

NCT04611503

Clinical

Trials by Indication[1]

Retinitis Pigmentosa1 trial

PDE6A Gene Therapy for Retinitis Pigmentosa

Active, not recruiting·SSTZ eyetrial·Phase 1/2·NCT04611503·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for subretinal injection of rAAV.hPDE6A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — subretinal injection of rAAV.hPDE6A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for subretinal injection of rAAV.hPDE6A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — STZ eyetrial company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 2[1]
Company: SSTZ eyetrial

subretinal injection of rAAV.hPDE6A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News